NOVO NORDISK A S
NVONYSE
$50.32
↓ -2.3%Jul 17 close · end-of-day
Price
1Y↓ -21.3%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
No screener snapshot for this ticker.
Company profile
Novo Nordisk A/S engages in the research, development, manufacture, and marketing of pharmaceutical products. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in areas of haemophilia, growth disorders, and hormone replacement therapy. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
- CEO
- Lars F. Jørgensen
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Employees
- 54,400
- Website
- novonordisk.com
Earnings
No reported earnings periods on file.
Financial statements
No annual data.
No quarterly data.
Company news
Jul 20, 2026
- 6h agoNovo Nordisk (CPSE:NOVO B) Launches Kyinsu In China Through Fangzhou Internet Hospitalfinance.yahoo.com
- 6h agoDoes EU Approval of Wegovy Pill Change NVO's Competitive Story?finance.yahoo.com
- 7h agoCiti lifts Novo Nordisk target on strong GLP-1 pill launchproactiveinvestors.com
- 8h agoNovo Nordisk A/S - share repurchase programmefinance.yahoo.com
- 18h agoFangzhou Launches Novo Nordisk’s Once-Weekly Basal Insulin/GLP-1 Therapy in Chinafinance.yahoo.com
Jul 18, 2026
Jul 17, 2026
- 3d agoWegovy Pill Just Changed the GLP-1 Market. Here's Why Eli Lilly Stock Could Still Winfool.com
- 3d agoThe Next Wave Of Peptides Could Be Here; What Does It Mean For Lilly, Novo?finance.yahoo.com
- 3d agoThe First Oral Cholesterol Pill Is Here. Which of These 5 Stocks Benefits Most?247wallst.com
- 3d agoThe weight-loss drugs boom is creating both winners and wipeouts: One Big Investment Ideafinance.yahoo.com
- 3d agoCompounders maintain a firm grip on the GLP-1 marketpharmavoice.com
- 3d ago3 High-Yield Dividend Stocks to Buy and Holdfool.com
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
No insider transactions in the last 12 months.
No insider transactions on file.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.